Phase 2 Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with clear cell kidney cancer (a specific type of kidney cancer) that has spread to other parts of the body
- Your cancer is progressing in only a small number of spots (5 or fewer areas)
- All of the spots where your cancer is progressing can be safely treated with radiation
- You have at least one area of disease that doctors can safely inject with the study drug (IMSA101)
- You are able to carry out at least some daily activities (your doctor will assess your general level of functioning)
- You are 18 years of age or older
- Your liver, kidneys, and bone marrow are working well enough, as confirmed by blood tests done within 14 days before joining the study
- All risk categories for kidney cancer (as measured by a standard medical scoring system) are welcome to apply
Who may not be able to join:
- You have cancer that is growing in or very close to the central airways or major blood vessels in the chest (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: RAQUIBUL HANNAN, MD, University of Texas Southwestern Medical Center
Phone: 214 648 1836
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate the PFS rate associated with the therapeutic intervention. PFS is defined as the duration of time from initiation of PULSAR/IMSA101 to disease progression as defined by RECIST1.1 or death.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.